Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P83369
UPID:
LSM11_HUMAN
Alternative names:
-
Alternative UPACC:
P83369; A0AVQ1; Q7Z7P0; Q8N975
Background:
U7 snRNA-associated Sm-like protein LSm11 plays a pivotal role in histone 3'-end pre-mRNA processing, essential for the regulation of gene expression. It is a component of the U7 snRNP complex, crucial for cell cycle progression from G1 to S phases. LSm11 binds specifically to the Sm-binding site of U7 snRNA, influencing U7 snRNA levels and, by extension, cellular function.
Therapeutic significance:
LSm11's involvement in Aicardi-Goutieres syndrome 8, characterized by severe neurological dysfunction and autoinflammation, underscores its therapeutic potential. Understanding LSm11's role could pave the way for innovative treatments targeting the cGAS-STING pathway, offering hope for patients with this debilitating condition.